Sepideh Gholami, M.D., F.A.C.S.

Assistant Professor, Department of Surgery

To see if Sepideh Gholami is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).




Surgery - Oncology

Hepatobiliary Surgery

Liver Cancer Surgery



Locations and Contact

2279 45th Street
Sacramento, CA 95817

Get Directions

Additional Numbers

Clinic Fax


Clinic Referral Phone


Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Gholami believes in an innovative, individualized, multi-disciplinary treatment approach to provide the most compassionate, highest quality of cancer care for her patients and their families. 

Clinical Interests

Dr. Gholami is a board-certified surgeon scientist with dual fellowship training in Complex General Surgical Oncology and Hepatopancreatobiliary Surgery. She believes in precision-medicine using evidence-based best practice to develop a personalized treatment plan for each patient.

Dr. Gholami specializes in surgeries of the gastrointestinal tract, liver, biliary tree, and the pancreas. Her clinical interests include innovative approaches to cancer care including minimally invasive surgery and robotic techniques as well as liver-directed therapies/regional therapies in patients with hepatobiliary and metastatic malignancies.

Research/Academic Interests

Dr. Gholami's research focus includes translational science and clinical trials to advance the understanding of hepatobiliary and pancreas tumor genetics, microenvironment, and immune profiling. She believes in innovative, personalized medical treatment through stratifying tumors on their genetic and immunologic features to achieve the best oncologic outcomes and highest quality of care.

Dr. Gholami has extensive research experience in vaccine and targeted therapies which have resulted in multiple publications and clinical trials. She is currently involved in developing clinical trials with novel therapeutics related to immune-activating agents as well as targeted therapies in combination with liver-directed/regional therapies in patients with hepatobiliary malignancies. In addition, Dr. Gholami is interested in clinical outcomes research to improve medical care related to cancer surgery at the National level. 


Surgical Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center
UC Davis Medical Group

Undergraduate School

B.S., UC Davis, Davis CA 2003

Medical School

M.D., Stanford University School of Medicine, Palo Alto CA 2008


General Surgery, Stanford University Hospital, Palo Alto CA 2008-2009


General Surgery, Stanford University Hospitals & Clinics, Palo Alto CA 2009-2010, 2012-2015


Complex General Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York NY 2015-2017


Hepatopancreatobiliary Surgery, Memorial Sloan Kettering Cancer Center, New York NY 2016-2017

UC Davis Cancer Pilot Grant, Comparative Oncology Program, 2020

Cancer Research Committee Award, University of California, 2020

SWOG Young Investigator Award, 2020

Paul Calabresi Career Development Award for Clinical Oncology, K12 Scholar, 2020

Society of Surgical Oncology Young Investigator Award, 2020

Association of Academic Surgeons Joel J. Roslyn Faculty Research Award, 2020

Association of Women Surgeons Fellowship Grant, 2020

UC Davis Cancer Pilot Grant for Young Investigators, 2019

Selected investigator -ASCO/AACR Methods in Clinical Cancer Research Workshop, 2019

Research Travel Grant, UC Davis Medical Center, 2019

Best Abstract, Annual Research Symposium, UC Davis, 2018

Research Travel Grant, UC Davis Medical Center, 2018

Hilary Sanfey Outstanding Resident Award (Association of Women Surgeons), 2014

Stanford General Surgery Resident Research Award, 2013

Recipient of the Nina Starr American Women Surgeon Research Award, 2012

Stanford General Surgery Resident Research Award, 2012

Highly-rated paper awardat (American Association of Cancer Research), 2012

Gholami S, Judge S, Stewart S, Gönen M, Allen P, Balachandran V, DeMatteo R, D'Angelica M, Jarnagin W, Kingham T. Is Minimally-invasive Surgery of Lesions in the Right Superior Segments of the Liver Justified? A Multi-institutional Study of 240 patients. J Surg Oncol. 2020 Aug 16. doi:10.1002/jso.26154.

Demisse R, Damle N, Kim E, Gong J, Fakih M, Eng C, Oesterich L, McKenny M, Ji J, Liu J, Louie R, Tam K, Gholami S, Halabi W, Monjazeb A, Dayyani F, Cho M. Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSIHigh Rectal Cancer: Case Series. J Natl Compr Canc Netw. 2020 Jul;18(7):798-804. doi:10.6004/jnccn.2020.7558. PMID:32634770.

Perry LM, Loehfelm T, Pillai R, Pan DY, Tejaswi S, Gholami S. Shifting the Treatment Paradigm for Pancreaticoportal Fistula Causing Hepatic Necrosis. Dig Dis Sci. 2020 Jul;65(7):1955-1959. doi:10.1007/s10620-020-06045-4. PMID:31919639.

Bateni SB, Johns AJ, Gingrich AA, Gholami S, Bold RJ, Canter RJ, Kirane AR. Elderly Age Is Associated With More Conservative Treatment of Invasive Melanoma. Anticancer Res. 2020 May;40(5):2895-2903. doi:10.21873/anticanres.14266. PMID:32366440.

Judge SJ, Ji J, Liu J, Kaur M, Kim E, Gong J, Tam KW, Kirane AR, Gholami S, Canter RJ, Bold RJ, Gangi A, Fakih M, Cho M. The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report. Front Oncol. 2020 Apr 21;10:581. doi:10.3389/fonc.2020.00581. PMID:32373540.

Gholami S, Grothey A. EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit? Lancet Oncol. 2020 Mar;21(3):324-326. doi:10.1016/S1470-2045(20)30003-6. Epub 2020 Jan 31. PMID:32014120.

Perry LM, Pan D, Loehfelm TW, Tejaswi S, Gholami S. Pancreaticoportal Fistula Causing Hepatic Necrosis Treated With Pancreatic Duct Stenting. Am J Gastroenterol. 2020 Feb 12. doi:10.14309/ajg.0000000000000554. PMID:32058345.

Gagnière J, Dupré A, Gholami S, Pezet D, Boerner T, Gönen M, Kingham TP, Allen PJ, Balachandran VP, De Matteo RP, Drebin JA, Yaeger R, Kemeny NE, Jarnagin WR, D'Angelica MI. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver? A Multi-institutional Analysis of 1497 Patients. Ann Surg. 2020 Jan;271(1):147-154. doi:10.1097/SLA.0000000000002968.

Gholami S, Shroff R. Adjuvant Therapy for Biliary Tract Cancer: Where We Are and Where We Want to Go. ASCO J Oncol Pract. 2019 Nov.

Leung M, Gholami S. The state of hepatic artery infusion chemotherapy in the management of metastatic colorectal cancer to the liver. Chinese Clin Oncol. 2019 Sep 30;8(5):54. doi:10.21037/cco.2019.09.01. PMID:31597435.

Gholami S, Boucher T, Kemeny N, Gonen M, Cercek A, Kingham P, Balachandran V, Allen P, DeMatteo R, Jarnagin W, D'Angelica M. Adjuvant Hepatic Artery Infusion Chemotherapy is Associated with Improved Survival Regardless of KRAS Mutation Status in Patients with Resected Colorectal Liver Metastases. Ann Surg. 2019 Feb 19. PMID:30817353.